Sanofi, OpenAI, Formation Bio launch Muse, an AI tool for patient recruitment
A flashy collaboration between Sanofi, OpenAI and Formation Bio produced its first AI-powered tool, aiming to speed up the process of recruiting patients into clinical trials. The tool is called Muse...
View ArticleTrace Neuroscience raises $101M for ALS and other neuro conditions
Trace Neuroscience, a startup spun out of Maze Therapeutics' pipeline, broke cover Tuesday morning with $101 million in funding to develop treatments for amyotrophic lateral sclerosis and other...
View ArticleRoche teams with Flare Therapeutics on transcription factors
Roche is aligning with Flare Therapeutics to work on small molecules for cancer by going after transcription factor targets, the companies said Tuesday morning. Cambridge, MA-based Flare has a...
View ArticleAlentis nabs $181M to broaden Claudin's scope in ADCs
Swiss biotech Alentis Therapeutics thinks it can expand the reach of the Claudin family in oncology, and half a dozen new investors are helping back the idea with a $181.4 million Series D. Tuesday's...
View ArticleAstraZeneca budgets another $2B to boost manufacturing and R&D in US
Among a flurry of third-quarter updates on Tuesday, AstraZeneca said it is earmarking an additional $2 billion to add 1,000 new jobs in the US. This is on top of the ...
View ArticleBayer not eyeing new deals to address Xarelto sales erosion
Bayer reiterated its plans to ride out the generic-driven sales decline of its thrombosis drug Xarelto, as the company’s shares plummeted to a record low because of lackluster third-quarter earnings....
View ArticleAstraZeneca, Daiichi Sankyo replace lung cancer filing for Enhertu successor
AstraZeneca and Daiichi Sankyo are changing the approval submission strategy for its planned Enhertu successor, datopotamab deruxtecan (Dato-DXd), after a few missed trials. The companies voluntarily...
View ArticleExclusive: GV-backed Medicaid startup Diverge Health raises $52M
A startup that helps low-income Medicaid members get the care they need and supports the doctors who work with them has raised $52 million, it confirmed to Endpoints News. Alphabet's venture arm GV led...
View ArticleApollo makes a deal worth up to $926M; Abeona resubmits gene therapy
Plus, news about Centessa, Autolus Therapeutics, Zucara Therapeutics, Vindur Tx, Vittoria Biotherapeutics and the MD Anderson Cancer Center: Apollo Therapeutics’ cardio-metabolic pact: The company will...
View ArticleMerck KGaA plans China submission after late-stage win for tumor drug
Merck KGaA’s experimental treatment for patients with tenosynovial giant cell tumors hit the primary endpoint in a Phase 3 study, and the company plans to submit the drug for approval in China with its...
View ArticleFDA commissioner warns of risk to agency under RFK Jr. influence
With just a few months to go before he likely steps down, President Biden's FDA Commissioner Rob Califf weighed in on how the agency might be affected by the incoming administration. Califf, while not...
View ArticleFDA denies Ocaliva full approval, but Intercept hopes to keep drug on market
The FDA rejected the full approval submission for Intercept Pharmaceuticals and Alfasigma’s primary biliary cholangitis treatment Ocaliva after safety concerns dogged the product, casting its future...
View ArticleMerck, AstraZeneca tout Phase 3 win for Koselugo in neurofibromatosis
Merck and AstraZeneca are hoping to expand the label of their MEK inhibitor Koselugo to certain adult patients with neurofibromatosis type 1 following a successful Phase 3 study. The companies
View ArticleSyndax's menin inhibitor succeeds in pivotal trial, but investors aren't...
Syndax Pharmaceuticals said its experimental menin inhibitor met the primary endpoint in a pivotal trial for certain leukemia patients, and it's planning a regulatory filing in the first half of 2025....
View ArticleAstraZeneca CEO reaffirms commitment to China following executive's detention
NEW YORK — AstraZeneca is not backing away from China despite an investigation into its president of China operations. As the company reported its third-quarter earnings, questions continued to swirl...
View ArticlePfizer looking to sell hospital drugs unit — reports
Pfizer is reportedly shopping its hospital drugs unit as it fends off scrutiny from activist investor Starboard Value. The plan was reported Tuesday by Reuters, which said Pfizer had tapped Goldman ...
View ArticleSyros' shares plummet as blood cancer drug fails again
Syros Pharmaceuticals’ stock price nosedived after its last drug candidate flunked a trial in hematological malignancies for the second time in recent months. In a 190-participant Phase 3 trial, the...
View ArticleBioNTech buys out partner Biotheus for PD-L1/VEGF cancer drug
After initially promising more than $1 billion in biobucks to its partner Biotheus for a single drug, BioNTech is now buying out all of the China-based company for $800 million in cash and as much ...
View ArticleExclusive: Flagship names two CEO-partners to lead Valo Health, Apriori Bio
Flagship Pioneering has appointed two new CEO-partners to advise its portfolio companies and help steer its spinouts Apriori Bio and Valo Health, the life sciences incubator and investor told Endpoints...
View ArticleTRexBio raises $84M to take in-house immune program into the clinic
Bay Area immunology biotech TRexBio has raised a $84 million Series B to start clinical studies of a potential treatment for atopic dermatitis and ulcerative colitis. The biotech’s lead candidate,...
View Article